m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00636)
Target Name pri-miR-27
Gene Name pri-miR-27
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
pri-miR-27 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 affected the growth, apoptosis, and stemness of MM cells through accelerating the stability of YY1 mRNA and the maturation of pri-miR-27 in vitro and in vivo.
Target Regulation Down regulation
Responsed Disease Multiple myeloma ICD-11: 2A83.1
 Disease Info 
Cell Process Cell apoptosis
In-vitro Model U266 (Human multiple myeloma cells)
RPMI-8226 Plasma cell myeloma Homo sapiens CVCL_0014
NCI-H929 Plasma cell myeloma Homo sapiens CVCL_1600
MM1.S Plasma cell myeloma Homo sapiens CVCL_8792
In-vivo Model BALB/C nude mice (5 weeks old, weighing 18-22 g) were fed in specific pathogen-free facilities and subcutaneously inoculated with U266 cells (1 × 106). The mice were randomly divided into 3 groups with 6 mice per group, when the tumor was measurable. Then, miR-27a-3p mimic or sh-METTL3 was injected intratumorally at an interval of 4 days a total of 4 times. Tumor volume was measured using a digital caliper every week and calculated using the formula V = 1/2 (width2 × length).
Multiple myeloma [ICD-11: 2A83]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 affected the growth, apoptosis, and stemness of MM cells through accelerating the stability of YY1 mRNA and the maturation of pri-miR-27 in vitro and in vivo.
Responsed Disease Multiple myeloma [ICD-11: 2A83.1]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Cell Process Cell apoptosis
In-vitro Model U266 (Human multiple myeloma cells)
RPMI-8226 Plasma cell myeloma Homo sapiens CVCL_0014
NCI-H929 Plasma cell myeloma Homo sapiens CVCL_1600
MM1.S Plasma cell myeloma Homo sapiens CVCL_8792
In-vivo Model BALB/C nude mice (5 weeks old, weighing 18-22 g) were fed in specific pathogen-free facilities and subcutaneously inoculated with U266 cells (1 × 106). The mice were randomly divided into 3 groups with 6 mice per group, when the tumor was measurable. Then, miR-27a-3p mimic or sh-METTL3 was injected intratumorally at an interval of 4 days a total of 4 times. Tumor volume was measured using a digital caliper every week and calculated using the formula V = 1/2 (width2 × length).
References
Ref 1 METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m(6)A-dependent manner. Cell Biol Toxicol. 2022 Jan 17. doi: 10.1007/s10565-021-09690-1. Online ahead of print.